

P&T Motion History
Calcitonin Gene-Related Peptide Inhibitors (CGRP)

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
eptinezumab erenumab fremanezumab galcanezumab	<p>After considering the evidence of safety and efficacy for the treatment of migraine prophylaxis, I move that erenumab, fremanezumab, galcanezumab are safe and efficacious for the treatment of their approved indications. The CGRP Inhibitors should be second line agents on the Washington PDL. Erenumab, fremanezumab, galcanezumab can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Eptinezumab should be considered not reviewed and not eligible to be preferred on the Washington PDL until higher quality evidence has been established.</p> <p>Motion: Figueroa 2nd: Park</p>	December 19, 2018	NA	No	Passed unanimous